Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 nov. 2019 08h35 HE
|
Cocrystal Pharma, Inc.
– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) – –...
Cocrystal Pharma Announces Clinical Trial Agreement for Investigator-Initiated Phase 2a Study in Hong Kong of CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
08 oct. 2018 08h00 HE
|
Cocrystal Pharma, Inc.
- Humanity & Health Research Centre to conduct Phase 2a study evaluating CC-31244 for the treatment of hepatitis C - Asia market represents one of the largest hepatitis C virus carrier...